These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16096432)

  • 1. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.
    Woodward JK; Neville-Webbe HL; Coleman RE; Holen I
    Anticancer Drugs; 2005 Sep; 16(8):845-54. PubMed ID: 16096432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.
    Neville-Webbe HL; Rostami-Hodjegan A; Evans CA; Coleman RE; Holen I
    Int J Cancer; 2005 Jan; 113(3):364-71. PubMed ID: 15455384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
    Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
    Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
    Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
    Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
    Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
    Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.
    Kopecka J; Porto S; Lusa S; Gazzano E; Salzano G; Pinzòn-Daza ML; Giordano A; Desiderio V; Ghigo D; De Rosa G; Caraglia M; Riganti C
    Oncotarget; 2016 Apr; 7(15):20753-72. PubMed ID: 26980746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
    Boissier S; Ferreras M; Peyruchaud O; Magnetto S; Ebetino FH; Colombel M; Delmas P; Delaissé JM; Clézardin P
    Cancer Res; 2000 Jun; 60(11):2949-54. PubMed ID: 10850442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
    Montague R; Hart CA; George NJ; Ramani VA; Brown MD; Clarke NW
    Eur Urol; 2004 Sep; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells.
    Ural AU; Avcu F; Candir M; Guden M; Ozcan MA
    Breast Cancer Res; 2006; 8(4):R52. PubMed ID: 16925824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
    J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
    Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
    Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro.
    Neville-Webbe HL; Evans CA; Coleman RE; Holen I
    Tumour Biol; 2006; 27(2):92-103. PubMed ID: 16582586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
    Pichot CS; Hartig SM; Xia L; Arvanitis C; Monisvais D; Lee FY; Frost JA; Corey SJ
    Br J Cancer; 2009 Jul; 101(1):38-47. PubMed ID: 19513066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
    Ottewell PD; Lefley DV; Cross SS; Evans CA; Coleman RE; Holen I
    Int J Cancer; 2010 Jan; 126(2):522-32. PubMed ID: 19621384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The geodiamolide H, derived from Brazilian sponge Geodia corticostylifera, regulates actin cytoskeleton, migration and invasion of breast cancer cells cultured in three-dimensional environment.
    Freitas VM; Rangel M; Bisson LF; Jaeger RG; Machado-Santelli GM
    J Cell Physiol; 2008 Sep; 216(3):583-94. PubMed ID: 18330887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells.
    Li XY; Lin YC; Huang WL; Hong CQ; Chen JY; You YJ; Li WB
    Med Oncol; 2012 Jun; 29(2):714-20. PubMed ID: 21431960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
    Dos Santos MP; de Farias CB; Roesler R; Brunetto AL; Abujamra AL
    Oncol Rep; 2014 Feb; 31(2):955-68. PubMed ID: 24316794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
    Vogt U; Bielawski KP; Bosse U; Schlotter CM
    Oncol Rep; 2004 Nov; 12(5):1109-14. PubMed ID: 15492801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?
    Michailidou M; Brown HK; Lefley DV; Evans A; Cross SS; Coleman RE; Brown NJ; Holen I
    J Vasc Res; 2010; 47(6):481-93. PubMed ID: 20431297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.